Gil M. Labrucherie Acquires 10,500 Shares of Septerna, Inc. (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie purchased 10,500 shares of the firm’s stock in a transaction on Wednesday, February 19th. The stock was acquired at an average cost of $5.51 per share, for a total transaction of $57,855.00. Following the completion of the purchase, the chief financial officer now owns 10,500 shares in the company, valued at $57,855. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Septerna Trading Down 1.5 %

Shares of NASDAQ:SEPN opened at $5.80 on Friday. Septerna, Inc. has a one year low of $4.17 and a one year high of $28.99. The company’s 50-day moving average is $17.78.

Institutional Investors Weigh In On Septerna

Several hedge funds have recently modified their holdings of SEPN. Tower Research Capital LLC TRC purchased a new stake in shares of Septerna during the 4th quarter valued at about $25,000. New York State Common Retirement Fund purchased a new stake in Septerna during the 4th quarter worth approximately $32,000. Legal & General Group Plc purchased a new stake in Septerna during the 4th quarter worth approximately $42,000. Summit Investment Advisors Inc. purchased a new stake in Septerna during the 4th quarter worth approximately $45,000. Finally, BNP Paribas Financial Markets purchased a new stake in Septerna during the 4th quarter worth approximately $52,000.

Analysts Set New Price Targets

SEPN has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $50.00 price target on shares of Septerna in a research note on Tuesday, February 11th. TD Cowen assumed coverage on Septerna in a research note on Tuesday, November 19th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. assumed coverage on Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price objective on the stock. Finally, Wells Fargo & Company lowered Septerna from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $43.00 to $14.00 in a research note on Tuesday.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.